Pfizer and BioNTech tease next-gen COVID-19 vaccine strategy

As federal officials wax poetic about the prospect of intranasal COVID-19 vaccines and other novel vaccine platforms, Pfizer Inc. (NYSE:PFE) and its partner BioNTech (Nasdaq:BNTX) have announced that a randomized Phase 2 study will study an incrementally improved COVID-19 vaccine known as BNT162b5.

The updated vaccine candidate includes a modified spike protein designed to bolster immunogenicity over the first-generation COVID-19 vaccine.

Pfizer notes that it plans on testing multiple vaccine candidates with the novel spike protein design to offer a more durable and broader immune response against SARS-CoV-2 infections and associated COVID-19.

The companies’ original BNT162b2 vaccine remains one of the most widely used worldwide. In 2021, the vaccine was the best-selling pharmaceutical product, generating $51.1 billion between Pfizer and BioNTech.

The bivalent BNT162b5 vaccine blends RNAs targeting the ancestral strain coronavirus and the omicron …

Read more
  • 0

Pfizer and BioNTech win EUA for booster for individuals 16 and older

Pfizer Inc. (NYSE:PFE) and its partner BioNTech SE (NSDQ:BNTX) have received emergency use authorization for BNT162b2 mRNA COVID-19 vaccine for individuals at least 16 years old.

To coincide with the announcement, CDC Director Dr. Rochelle Walensky recommended that everyone 16 and older receive a booster. “Although we don’t have all the answers on the Omicron variant, initial data suggests that COVID-19 boosters help broaden and strengthen the protection against Omicron and other variants,” Walensky said. Recipients need to wait at least six months after completing the primary vaccination series.

The Pfizer-BioNTech is now the only COVID-19 vaccine to win authorization for adolescents between 16 and 17.

“Today’s decision by the FDA to further expand the Emergency Use Authorization of a booster dose of our COVID-19 vaccine is a critical milestone as we continue to stay vigilant in addressing the virus,” said Albert Bourla, Pfizer CEO, in a press release.<…

Read more
  • 0